retatrutide glp-1 gip glucagon Science Behind GLP 1 and Receptor Agonists for Obesity Research | News & Announcements Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

A licensed provider reviews your health history, current medications, goals and whether the proposed treatment is appropriate for you

01 The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine

We know that it mimics a natural hormone called GLP-1, but many people also report that it helps quiet food noiseone of the biggest roadblocks for dieters

That creates a dangerous mismatch

Allergens:None

How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1